BioAge Labs, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutic candidates tied to human aging biology. The company's 8-K reports record periodic financial results, Regulation FD clinical updates for BGE-102, and disclosure of NLRP3 and APJ program development.
Other filings describe capital actions and governance, including common stock offering agreements under shelf registration statements, use-of-proceeds categories for research, clinical development, manufacturing and general corporate purposes, annual meeting proxy matters, director elections, auditor ratification, and board recommendations. These records also frame the company's capital structure and public-company reporting obligations.
BioAge Labs, Inc. reported that Chief Medical Officer Paul D. Rubin acquired a stock option award covering 110,000 shares of common stock. The option was granted at an exercise price of $0.00 per share and is held as a direct ownership position.
According to the vesting terms, the option vests in equal monthly installments of 1/48th of the total award. The first tranche vested on February 1, 2026, with each remaining monthly tranche scheduled to vest on the monthly anniversary of that date, as long as Rubin continues to provide service to the company on each vesting date.
Morgen Eric reported acquisition or exercise transactions in this Form 4 filing.
BioAge Labs, Inc. director and Chief Operating Officer Morgen Eric reported receiving new stock option awards. One option grant covers 110,000 shares held directly, and a separate option grant covers 12,500 shares held indirectly by the reporting person's spouse.
Each option vests in equal monthly installments of 1/48 of the total award, with the first tranche vested on February 1, 2026 and additional tranches vesting on each monthly anniversary. Vesting depends on continued service to BioAge Labs on each vesting date.
GOLDSTEIN DOV A MD reported acquisition or exercise transactions in this Form 4 filing.
BioAge Labs, Inc. reported that its Chief Financial Officer, Dov A. Goldstein, received a grant of stock options covering 110,000 shares of the company’s stock. The options were granted at no cash cost to the executive on the grant date.
According to the vesting terms, the award vests in 48 equal monthly installments. The first 1/48th portion vested on February 1, 2026, with each remaining monthly tranche vesting on the same monthly anniversary, so long as the CFO continues to provide service to BioAge on each vesting date.
Fortney Kristen reported acquisition or exercise transactions in this Form 4 filing.
BioAge Labs, Inc. director and Chief Executive Officer Kristen Fortney reported receiving a grant of stock options on February 17, 2026. The award covers 330,000 options with direct ownership. The options vest in equal monthly installments over four years, starting February 1, 2026, as long as she continues serving the company.
BioAge Labs, Inc. reported that Principal Accounting Officer Barton Shane received a grant of stock options covering 45,000 shares of common stock. The options were awarded at an exercise price of $0.0000 per share, reflecting a compensatory equity award rather than an open-market purchase.
According to the terms, the option vests in equal 1/48th monthly installments, with the first tranche vesting on February 1, 2026. Each subsequent tranche will vest on the monthly anniversary of that date, conditioned on Shane’s continued service with BioAge Labs on each vesting date.
BioAge Labs, Inc. shareholder ADAR1 Capital Management, LLC and Daniel Schneeberger report beneficial ownership of 135,560 shares of common stock, representing 0.4% of the outstanding shares. The stake is held through ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and other separately managed accounts as of December 31, 2025.
They report shared voting and dispositive power over all 135,560 shares, with no sole voting or dispositive power. The percentage is based on 35,855,037 shares outstanding as of October 31, 2025. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of BioAge Labs.
Cormorant Asset Management, LP and Bihua Chen have reported a passive 5.69% ownership stake in BioAge Labs, Inc. common stock. They beneficially own 2,040,605 shares, with no sole voting or dispositive power and all authority shared through Cormorant-managed funds.
The percentage is based on 35,855,037 BioAge shares outstanding as of October 31, 2025, as disclosed in the company’s Form 10-Q. The reporting persons certify that the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of BioAge Labs.
BioAge Labs, Inc. insider Kristen Fortney filed an amended Schedule 13G reporting beneficial ownership of 2,704,736 shares of the company’s common stock as of December 31, 2025. This represents 7.2% of BioAge’s outstanding common stock.
The position includes 1,210,056 shares directly owned by Dr. Fortney, stock options to purchase up to 1,459,187 additional shares held by her, and 35,493 shares underlying stock options held by her spouse, over which he has voting rights. The 7.2% figure is based on 35,855,037 shares outstanding as of October 31, 2025, as reported by the company.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin reported option exercises and a share sale in the company’s stock. On February 2, 2026, he exercised stock options for 5,433 shares at $4.11 and 2,000 shares at $6.57 of common stock.
On the same date, he sold 7,433 shares of common stock at $18.75 per share, leaving him with 0 shares of common stock held directly after the reported transactions. The filing notes that the sale was executed under a Rule 10b5-1 trading plan adopted on November 5, 2024. He continues to hold stock options, including awards that are fully vested or vest monthly over time.
BioAge Labs, Inc. Chief Financial Officer exercises stock options and acquires shares. On February 1, 2026, CFO Dov A. Goldstein exercised options to buy 3,541 shares of BioAge Labs common stock at $4.38 per share. Following this transaction, he directly owns 29,491 common shares and holds 162,917 stock options that are still outstanding.
The options vest in equal monthly installments over four years, with 1/48th of the award vesting each month starting on February 1, 2025, conditioned on continued service to the company.